Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Konecranes Plc: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10

KONECRANES PLC STOCK EXCHANGE RELEASE January 4, 2018  09.00 EETKonecranes Plc: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10Konecranes has on January 3, 2018, received a notification under Chapter 9, Section 5 of the Securities Market Act, according to which the total holding of BlackRock, Inc. in Konecranes Plc’s shares and votes has risen above 15 percent.On January 2, 2018, Blackrock Inc.’s total holding through shares and financials instruments amounted to 15.00 percent of Konecranes Plc’s shares and votes.Total positions of BlackRock, Inc.:

Peab builds apartments in Esbo, Finland

Peab has been commissioned to build 135 apartmentsin Esbo.  The customer is Kojamo GroupLumo-Kodit Oy, Finland’s largest private landlord.The contract is worth around EUR 14 million. Construction will commence in January 2018 and the apartments will be ready to move into in November 2019. The project was order registered in the fourth quarter of 2017.For further information, please contact:Mika Katajisto, CEO Peab Oy, cell: +358 40 570 1025Henrik Samuelson, temp Press Officer, cell: +46 725 33 45 85

Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes

Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, announced today the completion of enrollment for the international multi-center study Highdes.The study aimed to recruit 15-20 patients. A total of 18 patients have been treated with the company’s lead candidate IdeS and subsequently transplanted at five clinics in the US and Europe. All treated and transplanted patients will be followed up for six months. The primary objective of the study - to turn a positive cross-match test into a negative and thereby enable kidney

Bravida grows in Finland – acquires Adison Oy

Bravida acquires Finnish Adison Oy and strengthens its position as a multi-technical service provider in the fast-growing Helsinki region. The acquired company has about 70 employees and a turnover of approximately SEK 190 million.Adison Oy is a major supplier within replumbing and offers services in electricity, HVAC, ventilation and building construction. With the acquisition, Bravida achieves a stronger market presence in the important metropolitan area. – This is a strategic acquisition for Bravida. Our goal is to grow in Finland, and with this acquisition we become one of the major

MEDICOVER ACCELERATES INVESTMENTS IN INDIA

Medicover has increased its investments in the Indian hospital chain MaxCure ahead of previous discussed timetables. The initial ownership of 22% has been increased to 26.8% through an injection of new capital of EUR 2.6 million. The ownership is expected to be increased shortly to 37.2% via a secondary share purchase of EUR 3.4 million and an adjustment of share capital structure. This investment brings the total cost of current ownership in Maxcure to EUR 16.6 million. MaxCure will use the additional funds to expand existing hospital sites, acquire a minority in an existing subsidiary

Veidekke sold residential units at a value of NOK 5.7 billion in 2017

Veidekke sold 1,215 residential units in 2017, of which 210 were sold in Q4. The number of units in production was 3,173 and the sales ratio was 83% at year-end. Overall, Veidekke sold residential units at a value of NOK 5.7 billion in 2017 Veidekke sold 210 residential units in Q4 2017, which is on a par with Q3. The number of units in production increased somewhat compared to year-end 2016, and there were 3,173 units in production at year-end 2017, of which Veidekke's share was 2,505. The sales ratio for units in production was 83%. "Residential sales are on a par with Q3, but

Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients

Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the first four patients treated with ONCOS-102 followed by the checkpoint inhibitor (CPI) pembrolizumab (KEYTRUDA®) in patients with advanced melanoma whose disease has progressed after prior CPI treatment. This is the first time ONCOS-102 has been used therapeutically in melanoma patients, and also the first time the virus has been administered to CPI refractory patients. In this Phase I open

Elo renews infrastructure and cloud services agreement with Tieto

The Finnish mutual pension insurance company Elo and Tieto have entered into an agreement for the prolongation of the existing contract. This will be focused on cost efficiency and scalability for Elo, as well as a common transformation program, setting Elo up for future success.Under the five-year agreement, Tieto will provide Elo with infrastructure and cloud services, and create a scalable modern platform to help increase cost-efficiency and simplification as well as creating favourable conditions for Elo’s future business needs and an efficient value chain. The partnership will focus

Ambea acquires staffing business with school focus

Ambea acquires Elevhälsan from PR-vård group.  Elevhälsan focus on staffing solutions for primary and secondary school. Elevhälsan complement Ambeas existing staffing solutions and will be a part of Rent a Doctor and Nurse.Elevhälsan started in 2005 and offers staffing solutions and comprehensive solutions for care provider responsibility (vårdgivaransvar). Elevhälsan offers school nurses, school doctors, counselors and psychologists. Elevhälsan is represented all over Sweden with a strong position in Stockholm, Uppsala and Östergötland. Revenue for 2016 was approx. SEK 22 million. For

Not a Single Story – A Collaboration between NIROX Foundation, South Africa and The Wanås Foundation, Sweden

From 12 May 2018 until the end of July, NIROX Foundation in South Africa will host Not a Single Story – The Winter Sculpture Exhibition, co-curated by Elisabeth Millqvist and Mattias Givell, the leadership duo behind the Swedish sculpture park The Wanås Foundation – Wanås Konst. The exhibition is an exchange between sculpture parks on two continents looking at individual artistic practices as overlapping dialogues and bring forward contemporary concerns and working methods related to sculpture. When we realize that there is never a single story about any place we regain a kind of paradise.

Changes in Enviro’s Election Committee

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. The Election Committee of Scandinavian Enviro Systems AB has changed with the appointment of Stefan Persson, representing Mardal Invest AB.Enviro’s Election Committee as per January 1st, 2018: · Stefan Winström (chairman, appointed by KL Ventures II AB) · Lennart Persson (shareholder) · Stefan Persson (appointed by Mardal Invest AB) · Stig-Arne Blom (Chairman of the Board, Enviro) The

Panion’s epilepsy product candidate for gene therapy in the dog: FDA has established an Investigational New Animal Drug (INAD) file.

Panion Animal Health AB (“Panion”) has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection. A summary of the scientific rationale for the therapy and the preliminary work completed to date was submitted and the FDA accepted this with a

Exchange rates for the fourth quarter of 2017

The net foreign exchange impact of the Kindred Group’s main trading currencies against its reporting currency of GBP is shown in the tables below. While this has no material impact on the underlying development in Kindred Group’s business, it does affect the reported results when translated into GBP. The weighted average impact of GBP against Kindred Group’s main currencies was a positive impact on Gross winnings revenue of approximately 1 per cent in the fourth quarter of 2017 compared to the same period of 2016. Balancesheetrates:Rate to 31-Dec-17 31-Dec-16 YoY

Invitation to presentation of Dustin´s Interim Report on January 10

Dustin Group will hold a conference call for investors, analysts and media on January 10 at CET 09:00 am with reference to the release of the Interim report for the first quarter.CEO Thomas Ekman and CFO Johan Karlsson will present the financial results for the first quarter 2017/18 and answer questions. The conference call will be held in English. Related presentation material will be available at the corporate website www.dustingroup.com under Financial information http://www.dustingroup.com/en/reports-and-presentations before the start of the conference call. Dustin Group will publish

Tecnotree’s Financial Reporting and Annual General Meeting in 2018

Tecnotree CorporationStock Exchange Release3 January 2018 at 4.30 pm EETTecnotree will publish its financial statement report 2017 on Friday, 23 March 2018.Tecnotree’s financial reports in 2018 will be released as follows:- Interim report 1-3/2018: Thursday, 26 April 2018- Half year report 1-6/2018: Friday, 10 August 2018- Interim report 1-9/2018: Friday, 26 October 2018Tecnotree will publish 1-3/2018 and 1-9/2018 financial reports as summary versions including interim balance sheet and events during the period.The company applies 30 days quiet period before the publication

Nuevolution to receive license fee payment of USD 750,000

Stockholm, 3 January 2018. Nuevolution AB (publ) (NUE.ST) today announced that Janssen Biotech, one of the Pharmaceutical Companies of Johnson & Johnson, has exercised its option to license one of the research programs under the multi-target collaboration entered between the parties in October 2015 – a collaboration that was expanded further in April 2016 and March 2017. The program that has been licensed to Janssen Biotech relate to a disease target in the therapeutic area of anti-infectives. Nuevolution will initially receive a license fee of USD 750,000 (SEK 6.11 million) for the

High-Performance Canadian Facility to Deploy Heliospectra LED Grow Lights for Medicinal Cannabis Cultivation in 2018

Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouses and controlled farming environments, announces an order from a value-added reseller for a customer building a high-performance medicinal cannabis cultivation facility in Eastern Canada. The order for the Heliospectra LX60 intelligent LED lighting solution is valued at SEK 5,488,411 (USD $651,200).Heliospectra’s industry-leading LED grow lights and software control enable commercial growers to accelerate harvest and production cycles while delivering consistent yields

Popular Wireless Conference Phone Unbundled for Increased Flexibility

Konftel is making their popular conference phone Konftel 300Wx available in North America and Canada without the analog DECT base station. The separate conference phone is sold for $100 less than the original bundle. Customers now have more flexibility in terms of choosing network access in a cost effective way.– The wireless conferencing trend is strong in North America and we see a huge demand for the very powerful and wireless conference phone Konftel 300Wx, says Torbjörn Karlsson, Product Manager at Konftel. Companies of all sizes are also looking for multiple connectivity options for

Cybaero intensifies search for new CEO and CFO

CybAero intensifies the search for new CEO ready to continue and push CybAero towards the future. At the same time, searches for new CFO has also begun.The Board announces that, with the help of Novare Executive Search, they seek successor for Mikael Smith who has chosen new challenges outside the Company. Smith will be working during the notice period.               The Board thanks Mikael Smith for his dedicated work as CFO, and later also interim CEO, where Smith has, with the greatest commitment, successfully led CybAero through positive changes and successful financing. "In 2017

#18-10 Listing of Knock out warrants issued by Commerzbank AG

As from January 04, 2018, 7 Knock out warrants issued by Commerzbank AG will be listed on ETP Finland and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Finland Oy.Issuer: Commerzbank AG Type of security: Knock out warrants, open ended Execution: Automatic cash settlement Term: As from January 04, 2018 and forward or until time for knock out event Market Maker: Commerzbank AG Underlying: DAX 30 Index Current values of strike and barrier can be found at: [ NGM Market Data Web - KnockOutWarrants ] 

#18-9 Listing of Mini futures issued by BNP Paribas Issuance B.V.

As from January 04, 2018, 29 Mini futures issued by BNP Paribas Issuance B.V. will be listed on ETP Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Mini futures, open ended Execution: Automatic cash settlement Term: As from January 04, 2018 and forward or until time for knock out event Market Maker: BNP Paribas Arbitrage SNC Underlying: ABB Ltd Africa Oil Corporation Assa Abloy AB ser.B Boliden AB Electrolux AB ser. B Fingerprint Cards AB ser

#18-8 Name change on instrument issued by UBS AG

After today´s trading, 1 instrument issued by UBS AG will change long name.+------------------------------------------------------------+---------------+|Old name |New Name |+------------------------------------------------------------+---------------+|Product Description Gearing Certificate on European Indices,|SYDEUROPA 1709H||2017-2021 with no Nominal Capital Protection | |+------------------------------------------------------------+---------------+ For more details see attached file.

Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013

Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc. The milestone payment is for the partnership agreement to initiate a clinical combination study of ADC-1013 with one of Janssen’s proprietary PD-1 inhibitors. This is the first out of a number of pre-defined milestones, related to the

Alma Media invests strongly in data-driven service and experience

Alma Media Corporation                                                             Press Release January 3, 2018 ALMA MEDIA INVESTS STRONGLY IN DATA-DRIVEN SERVICE AND EXPERIENCE Alma Media, a media company focusing on digital services and publishing, will deploy Salesforce DMP (Data Management Platform). The deployment will strengthen the development of the data-driven customer experience of Alma’s content and services as well as marketing automation and the targeting of digital advertising. Salesforce DMP will allow Alma to take advantage of its full data potential: the platform

There are no items matching the current filter
There are no more items matching the current filter
Back to top